X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AbCheck’s broad discovery platform and deep expertise in antibody generation and optimization will enable cost-effective and strategic acceleration of Ampersand’s AND™ Platform, to generate AND-Body™ Therapeutics, programmed biologics across a broad range of diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Ampersand Biomedicines
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 03, 2024
Details:
AbCheck’s novel microfluidics technology is designed to discover antibodies to very challenging targets, aiming to provide novel treatment options in disease areas with high medical need such as neurological disorders, inflammatory diseases and oncology.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Czech Republic
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Funding March 09, 2023
Details:
Under the terms of the agreement, AbCheck will apply its proprietary technology suite comprising a tailored combination of state-of-the-art antibody discovery technologies to delivering antibodies against an undisclosed target for peripheral neural response.
Lead Product(s): Antibody
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 21, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
